Metastatic Cancer Research
NCI-MATCH Trial (Molecular Analysis for Therapy Choice)Updated: June 6, 2017
Information about the NCI-MATCH precision medicine trial, in which researchers will examine tumor tissue from patients with advanced solid tumors and lymphomas that have stopped responding to treatment and assign patients to treatment arms based on the molecular profiles of their disease.
Study Identifies Genetic Mutations in Tumors From 10,000 Patients with Metastatic CancerPosted: May 31, 2017
Researchers at Memorial Sloan Kettering Cancer Center have reported the results of an initiative to characterize the genetic mutations in tumors from more than 10,000 patients with advanced cancer treated at the center.
Less-Frequent Zoledronic Acid Treatment Effective at Preventing Bone Metastasis ComplicationsPosted: January 30, 2017
In a clinical trial involving patients with metastatic cancer, administration of zoledronic acid every 12 weeks was as effective at preventing skeletal-related events caused by bone metastases as administration every 4 weeks.
Immune-Cell Traps May Aid Cancer MetastasisPosted: December 6, 2016
Cancer cells may exploit a normal function of neutrophils, the most common form of white blood cell, to help form metastatic tumors, a new study suggests.
Trial of Pembrolizumab for HIV-Positive Patients with Recurrent or Refractory CancerPosted: May 19, 2016
In this phase I clinical trial, HIV-positive patients receiving combination antiretroviral therapy who have cancer that has recurred after or has not responded to previous treatment will receive the immune checkpoint inhibitor pembrolizumab.
Whole Brain Radiation for Some Patients with Brain Metastases Worsens Cognitive DeclinePosted: June 2, 2015
In some patients with cancer that has spread to the brain, whole brain radiation following radiosurgery causes more severe cognitive decline and does not improve survival compared with radiosurgery alone, a new study has found.
Genetically Engineered Immunotherapy for Advanced CancerPosted: August 7, 2012
In this trial, doctors will collect T lymphocytes from the blood of patients with advanced mesothelin-expressing cancer and genetically engineer these cells to recognize mesothelin. The gene-engineered cells will then be multiplied and infused into the patients to fight their cancer.
Matters of the Heart: Why Are Cardiac Tumors So Rare?Posted: February 10, 2009
Cardiac tumors that originate in the heart itself are extremely rare. The highly specialized and most abundant cell in the heart may explain why the organ is such an inhospitable host to cancer.